Skip to main content
Back to News
OpenEvidence reached a 12 billion dollar valuation after a 250 million dollar funding round led by T...
Funding
1 min read
US

OpenEvidence reached a 12 billion dollar valuation after a 250 million dollar funding round led by T...

The AMW Read

OpenEvidence's $12B valuation and massive physician penetration validates the high-scale potential of vertical AI, while the $250M round and $12B valuation trigger the cross.Β§D threshold.
NoveltySignificance
Healthcare & Bio Β· Player MapCapital Cycles

OpenEvidence reached a 12 billion dollar valuation after a 250 million dollar funding round led by Thrive Capital. Used by 50 percent of U.S. physicians and processing 18 million monthly consultations, the startup proves vertical AI can scale as fast as general models. This signals a systemic shift toward domain-specific intelligence where precision is non-negotiable. Its ad-based revenue model suggests a new path for AI monetization beyond traditional SaaS. πŸš€

#AI #HealthTech #OpenEvidence

How This Connects

Based on Healthcare & Bio Β· Player Map

  1. 2w agoSkyLabs Sets September KOSDAQ Listing, Discloses $18.4M H1 2026 Revenue and Otsuka Distribution DealSkyLabs
  2. 1mo agoCuspAI raises $450M at $2.6B valuation for AI materials discovery, enlists Nvidia, Meta, Samsung in foundry coalitionCuspAI
  3. 1mo agoColossal Biosciences seeks funding at $20-30B valuation for AI-driven de-extinction technologyColossal Biosciences
  4. 7mo agoOpenEvidence reached a 12 billion dollar valuation after a 250 million dollar funding round led by T... Β· THIS ARTICLE

Related News

More news from OpenEvidence

Stay updated with the latest news and announcements from OpenEvidence.

View all OpenEvidence news

Discover AI Startups

Explore 5,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard